Methods for modulating expression of C9ORF72 antisense transcript

US11162096B2 · kind B2 · utility

Assignees

• Ionis Pharmaceuticals, Inc. · US
• The Regents of the University of California · US
• Ludwig Institute for Cancer · US

Inventors

• C. Frank Bennett · Carlsbad, US
• Frank Rigo · Carlsbad, US
• Don W. Cleveland · Alameda, US
• Clotilde Lagier-Tourenne · Winchester, US
• John M. Ravits · Village of La Jolla, US
• Michael W. Baughn · Village of La Jolla, US

Key dates

• Filing date: Dec 20, 2017
• Grant date: Nov 2, 2021
• Expiry date: Dec 20, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.